At the time that they had to choose where to go with their next low-impact, ADHD looked like a more promising partnering context than Fragile X. Fragile X has heated up over the past 12-18 months as a favored indication, even as ADHD has receded--Fragile X was hardly ever mentioned before then, and even now, there are only two major pharmas actively pursuing it, plus Seaside.
Plus: They know ADHD is addressed by low-impact Ampakines, Fragile X would probably be better served by a high-impact....
NeuroInvestment
News 
Market Data 
Discover 
